We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Study Investigates Survival Rates of Bladder Cancer Patients

By MedImaging International staff writers
Posted on 06 Jun 2017
A large-scale study of cancer patients has revealed that was no difference between the survival rates following radical bladder removal surgery compared to bladder-preserving combined modality treatment.

The researchers looked at data from 19 previously published cancer research papers including 12,380 patients with Muscle-Invasive Bladder Cancer (MIBC).

The research was published in the April 1, 2017, issue of the International Journal of Radiation Oncology*Biology*Physics, of the American Society for Radiation Oncology by researchers from the University of Texas Health Science Center (UT Health San Antonio; San Antonio, TX, USA).

The researchers compared overall 10-year survival, progression-free survival, disease-specific survival, complications as a result of radical cystectomy treatment, and Combined Modality Treatment (CMT) that consisted of Radiation Therapy (RT), chemotherapy, and transurethral resection of the tumor.

The researchers concluded that CMT could be considered as a standard first approach for patients with muscle-invasive bladder cancer (MIBC) instead of the current standard of Radical Cystectomy (RC), which necessitates additional surgery to construct a new urine storage system for the patient.

Senior author of the study, assistant professor Dharam Kaushik, MD, UT Health San Antonio, said, "These results provide compelling evidence suggesting radiation therapy may be as good as surgery for many of these patients. We hope this study will help patients and their physicians understand the full range of options available when planning treatment for muscle-invasive bladder cancer. According to our analyses, patients undergoing radical cystectomy likely share no cancer survival benefits compared with patients receiving chemoradiation-based bladder preservation therapy. Further research is needed to evaluate these two treatment arms – radical cystectomy versus combined modality treatment – to identify optimal treatments for specific patients."

Related Links
University of Texas Health Science Center

Medical Radiographic X-Ray Machine
TR30N HF
Pocket Fetal Doppler
CONTEC10C/CL
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Mammography System (Analog)
MAM VENUS

Channels

Nuclear Medicine

view channel
Image: LHSCRI scientist Dr. Glenn Bauman stands in front of the PET scanner (Photo courtesy of LHSCRI)

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more

General/Advanced Imaging

view channel
Image: Concept of the photo-thermoresponsive SCNPs (J F Thümmler et al., Commun Chem (2025). DOI: 10.1038/s42004-025-01518-x)

New Ultrasmall, Light-Sensitive Nanoparticles Could Serve as Contrast Agents

Medical imaging technologies face ongoing challenges in capturing accurate, detailed views of internal processes, especially in conditions like cancer, where tracking disease development and treatment... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.